Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $18.00 target price on the stock.

Separately, Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, March 20th.

Coya Therapeutics Trading Up 5.8 %

Shares of COYA opened at $6.89 on Thursday. The company has a market cap of $115.24 million, a price-to-earnings ratio of -10.60 and a beta of 0.31. The business’s fifty day simple moving average is $6.41 and its two-hundred day simple moving average is $6.51. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of COYA. Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $401,000. CM Management LLC raised its position in Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after acquiring an additional 15,941 shares during the period. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics during the 4th quarter worth $74,000. Finally, Northern Trust Corp boosted its stake in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.